Navigation Links
eBioscience Corporation Announced Today That James Glynn Has Been Appointed to Its Board of Directors, Effective April 15, 2008
Date:4/15/2008

SAN DIEGO, April 15 /PRNewswire/ -- Mr. Glynn has over 34 years of combined financial, operating and director level experience, and is well known within the life sciences industry for his role in the growth and development of several biotechnology companies. Most notably, Mr. Glynn retired from Invitrogen Corporation (Nasdaq: IVGN) in 2003 where, during his tenure with the company, he held several operating roles including CFO, President and COO and CEO. During this time, Mr. Glynn led the company through several stages of growth including an IPO, numerous financings and several acquisitions including Novex, GIBCO Life Technologies, Research Genetics and Molecular Probes. Mr. Glynn, following his retirement from Invitrogen Corporation, remained on the company's board of directors until April 2006.

"We are very pleased to be adding someone of Jim's reputation and experience to our board," said Todd R. Nelson Ph.D., eBioscience's Chief Executive Officer. "As an emerging global leader in the cellular analysis market, we are focused on growing our business operations through the development and commercialization of a diverse array of products, and also through the operational execution of several key strategic initiatives. In his role as director, Mr. Glynn will provide invaluable operating insight, financial advice and strategic guidance to ensure eBioscience remains a leader in the life sciences market place." Brian Seed Ph.D., Chairman of the board of directors for eBioscience added, "We look forward to tapping Jim's wealth of operating wisdom and the insights gleaned from his decades of senior management experience in the life science and related industries. Jim enjoys an enviable reputation among investors and professional fund managers for his business insight, strategic acumen, and proven ability to contribute guidance at the board level."

Prior to joining Invitrogen Corporation in 1998 as the company's CFO, Mr. Glynn served as CFO for Matrix Pharmaceutical, Inc. from 1995 to 1998 and as CFO for Mycogen Corporation from 1987 to 1995. Prior to that he was Vice President, Finance & Treasurer of Lubrizol Enterprises, Inc. and an Audit manager for Price Waterhouse & Co. from 1974 to 1982.

Mr. Glynn currently serves as a director for Alphatec Spine, Inc. and American Specialty Health.


'/>"/>
SOURCE eBioscience Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
2. Sumitomo Corporation of America Named Exclusive Distribution and Sales Agent for Chiral Quest
3. IBF Conferences Inc*International Business Forum and BioEnterprise Corporation present the 2nd Annual Global Healthcare Investing Conference
4. Sigma-Aldrich Corporation 1st Quarter 2008 Earnings Conference Call
5. Kensey Nash Corporation Announces Its Third Quarter 2008 Earnings Release Date and Teleconference
6. Chem Rx Corporation Reports Full Year 2007 Financial Results
7. Chem Rx Corporation Postpones Conference Call to Review Full Year 2007 Financial Results
8. Genaera Corporation Announces 2007 Financial Results
9. Chem Rx Corporation Schedules Conference Call to Review Full Year 2007 Financial Results
10. Immunosyn Corporation Announces 2007 Results, Files 10KSB
11. Spectros Corporation Reports 2007 Year-Over-Year Sales Rise 36%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... 20, 2017 http://www.Financialbuzz.com ... of leading causes of death worldwide. There were 8.2 ... of cancer related deaths increased gradually over time, the ... rate of various cancers continues to drive demand of ... by Global Market Insights, Inc. cancer biological therapy market size ...
(Date:1/19/2017)... -- Research and Markets has announced the addition of ... Application - Global Opportunity Analysis and Industry Forecast, 2014-2022" report ... ... projected to reach $15,737 million by 2022 from $6,521 in 2015, ... Omic technologies segment accounted for more than half of ...
(Date:1/19/2017)... HOUSTON , Jan. 19, 2017 ... announced the formation of its Medical/Clinical Advisory Board. ... industry veterans who enhance the range and depth ... development of its novel prenatal diagnostic tests.  These ... and strategic guidance for the company,s product development ...
(Date:1/19/2017)... and Markets ... addition of the "Implantable Biomaterials Market Analysis & ... to their offering. Report Highlights: ... current and future market trends to identify the investment opportunities ... numbers Key market trends across the business segments, Regions ...
Breaking Biology Technology:
(Date:12/16/2016)... -- The global wearable medical device market, in terms of value, ... 5.31 billion in 2016, at a CAGR of 18.0% during the ... ... medical devices, launch of a growing number of smartphone-based healthcare apps ... providers, and increasing focus on physical fitness. Furthermore, ...
(Date:12/15/2016)... HILLS, Mich. , Dec. 15, 2016  There ... unlocking car doors or starting the engine. Continental will ... in Las Vegas . Through the ... (Passive Start and Entry) and biometric elements, the international ... field of vehicle personalization and authentication. "The ...
(Date:12/7/2016)... According to a new market research report "Emotion Detection and Recognition Market ... Application Area, End User, And Region - Global Forecast to 2021", published by ... 2016 to USD 36.07 Billion by 2021, at a Compound Annual Growth Rate ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):